Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials

Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, ...
Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, ...
Genome & Company, a South Korean developer of microbiome-based drugs, on Tuesday said its GEN-001, a leading immunotherapy drug candidate for bi...